The Global Summit on Regulatory Science (GSRS) is an international conference for discussion of innovative technologies and partnerships to enhance translation of basic science into regulatory applications within the global context. The conference provides an opportunity for scientists from government, industry, and academic-research communities to objectively assess the utility of emerging technologies (such as nanotechnology, imaging, omics for translational science, personalized medicine, medical product safety, and food safety) for addressing regulatory-research questions and to discuss the best way to translate these technologies into real-world applications. The conference provides a platform where regulators, policy makers, and bench scientists from various countries can exchange views on how to develop, apply, and implement innovative methodologies into regulatory assessments in their respective countries, as well as harmonizing strategy via global collaboration. To engage the global community to address regulatory-science research and training needs, GSRS will be held in different countries on an annual basis.
GSRS20 — Maryland
Emerging Technologies and Their Application to Regulatory Science
September 28-30, 2020
Summary of GSRS19 — Lago Maggiore, Stresa, Italy
The 9th Global Summit on Regulatory Science (GSRS19) on Nanotechnology and Nanoplastics was held from 24-26 September 2019, at Lago Maggiore, Stresa, Italy. The ninth annual summit was co-organized by the Global Coalition for Regulatory Science Research (GCRSR) and Joint Research Center (JRC), European Commission. GCRSR is co-chaired by Drs. William Slikker (FDA) and Marta Hugas (EFSA). The summit had 200 scientists in attendance from 34 countries representing regulatory and research institutes along with academic and industry participants to present on the regulatory science perspective, current status, knowledge gaps and future outlook. The summit topics and sessions were developed by the scientific program committee composed of GCRSR member agencies co-chaired by Drs. Anil Patri (FDA) and Birgit Sokull-Kluettgen (JRC/EC) and included plenary sessions on perspectives from regulatory agencies and others with parallel sessions on drugs, foods, devices, nanotoxicology, and standards.
The summit was a huge success with presentations from appropriate regulatory/research authorities with in-depth scientific presentations on current nanotechnology applications and panel discussions. A limited number of academic and industry presenters were invited to showcase cutting edge research, successes, ongoing clinical trials and challenges. The scientific content of the summit is unique, different from traditional scientific conferences, with a focus on regulatory science, knowledge gaps, and how to address these gaps through global collaborations and specific mechanisms utilized for this purpose. The plenary session on Nanoplastics brought together current state of the art in microplastics, the concerns, research efforts, potential health effects, emphasizing the lack of information and data on nanoplastics. There were pre- and post-meeting training sessions sponsored by JRC at their facility in Ispra, lab tours of the Nanobiotechnology Center, and an American Society for Testing and Materials (ASTM) International E56 ASTM E56 meeting on Nanotechnology standards. The scientific program committee will work on a draft summary report from the meeting and come up with summary recommendations on potential global collaborations to address the knowledge gaps.
Over 200 scientists from 13 countries attended GSRS18.